The Concept of Cancer Translational Research - A Review

Main Article Content

S. Ramachandran
Ramam Sripada
Lakshmi Himaja Bandaru
P. Himasree

Keywords

Chemotherapy, Oncology, Palliative care, Translational Research

Abstract

The translational research is a multidisciplinary research model which includes the process of discovering the concepts of research by using basic science and applying that knowledge with in the clinical praxis. This model appears to be well constructed and highly systematic and it bridges the concept of basic research and the clinical practice. This research paradigm is one of the basis for developing translational medicine which leads to progression of evidence based medicine to solve the public health issues. In this review, the concept of translational research along with various stages, cancer therapeutics & prevention, the main reasons for inadequate therapeutics along with contemporary and future perspectives were discussed. The terminal goal of translational research is to identify the therapeutic guidelines and regimes which are highly effective with low toxicity. The evolution of biotechnology lead to the development of indisputable chances for ameliorating the ability to diagnose, treat and prevent the neoplasms. Preclinical investigations are undergoing for latest developments and advancements in the molecular biology or molecular targeted therapies which lead to the increased identification of the latest agents for treatment. For the expected quality of oncological practice large variety of molecular tumor characteristics and their supporting models will be helpful for allowing continuous reassessment of human malignancies at molecular level. In conclusion, translational research can be used to improve the public health outcomes and can develop the therapeutic and preventive strategies regarding various diseases or disorders and can provide cost benefit health care analysis. Thus, consistent efforts in translational research stimulate the logical and reasonable inventions in the field of multidisciplinary cancer research in future.

Abstract 137 | pdf Downloads 88

References

1. Choi PJ, Tubbs RS, Oskouian RJ. The Current Trend of the Translational Research Paradigm. Cureus. 2018; 10(3): e2340.
2. Mehic B. Translational research in medicine. Bosn J Basic Med Sci. 2011 May;11(2):73.
3. Gonzales R, Handley MA, Ackerman S et al. A framework for training health professionals in implementation and dissemination science. Acad Med. 2012; 87:271-8.
4. Dilmore TC, Moore DW, Bjork Z. Developing a competency-based educational structure within
clinical and translational science. Clin Transl Sci. 2013; 6:98–102.
5. Munoz DA, Nembhard HB, Kraschnewski JL. Quantifying complexity in translational research: an integrated approach. Int J Health Care Qual Assur. 2014; 27:760–76.
6. Griswold-Theodorson S, Ponnuru S, Dong C et al. Beyond the simulation laboratory: A realist synthesis review of clinical outcomes of simulation-based mastery learning. Acad Med. 2015; 90:1553- 60.
7. Hiss RG. USA: Natcher Conference Center, National Institutes of Health, Bethesda, Maryland; 2004. Fundamental issues in translational research. Translational research—two phases of a continuum. In: From clinical trials to community: the science of translating diabetes and obesity research; pp. 11–4.
8. Peyraud F, Cousin S, Italiano A. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep. 2017; 19:70.
9. Zarbin M. What Constitutes Translational Research? Implications for the Scope of Translational Vision Science and Technology. Transl Vis Sci Technol. 2020 Jul 14; 9(8):22.
10. Vukotich CJ. Jr. Challenges of T3 and T4 translational research. J Res Pract. 2016;12:P2.
11. Khoury MJ, Gwinn M, Yoon PW et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med. 2007; 9: 665–74.
12. Westfall JM, Mold J, Fagnan L. Practice-based research–“Blue Highways” on the NIH roadmap. JAMA. 2007; 297:403–6.
13. Fort DG, Herr TM, Shaw PL et al. Mapping the evolving definitions of translational research. J Clin Transl Sci. 2017;1: 60–6.
14. Ringborg U. Translational cancer research - a coherent cancer research continuum. Mol Oncol. 2019 Mar;13(3):517-520.
15. McGartland Rubio D, Schoenbaum EE, Lee LS et al. Defining translational research: implications for training. Acad Med. 2010; 85: 470–5.
16. Calvo F, Apolone G, Baumann M et al. Cancer Core Europe: a European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. Eur J Cancer. 2018; 103:155–9.
17. Forman D, Bauld L, Bonanni B et al. Time for a European initiative for research to prevent cancer: a manifesto for Cancer Prevention Europe (CPE). J Cancer Policy. 2018; 17:15–23.
18. Lacombe D, Bogaerts J, Tombal B et al. Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society. Mol Oncol. 2019; 13: 558–66.
19. Jonsson B and Sullivan R. Mission-oriented € translational cancer research – health economics. Mol Oncol. 2019; 13: 636– 47.
20. Lagergren P, Schandl A, Aaronson NK et al. Cancer survivorship: an integral part of Europe’s research agenda. Mol Oncol. 2019; 13:624-35.
21. Oberst S. Bridging research and clinical care – the comprehensive cancer centre. Mol Oncol. 2019; 13:614–18.
22. Goldblatt EM, Lee WH. From bench to bedside: the growing use of translational research in cancer medicine. Am J Transl Res. 2010 Jan 1; 2(1):1-18.
23. Bernier J, Hall EJ et al. Radiation oncology: A century of achievements. Nat Rev Cancer. 2004; 4:737- 47.
24. Haffty BG, Kim JH et al. Concurrent chemo-radiation in the conservative management of breast cancer. Int J Radiat Oncol Biol Phys.2006; 66:1306-12.
25. Hirbe A, Morgan EA, Uluçkan O et al. Skeletal Complications of Breast Cancer Therapies. Clin Cancer Res. 2006; 12:6309-14.
26. Munshi A. Breast cancer radiotherapy and cardiac risk: The 15-year paradox! J Cancer Res Ther. 2007; 3:190-2.
27. Torres-Roca JF and Stevens CW. Predicting Response to Clinical Radiotherapy: Past, Present, and Future Directions. Cancer Control. 2008; 15:151-6.
28. Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomed. 2008; 3:181-99.
29. Van Meerbeeck JP, Meersschout S, de Pauw R et al. Modern Radiotherapy as Part of Combined Modality Treatment in Locally Advanced Non-Small Cell Lunch Cancer: Present Status and Future Prospects. The Oncologist. 2008; 13:700-8.
30. Scott RB. Cancer Chemotherapy- The First Twenty-five Years. British Med J. 1970; 4:259- 65.
31. Devita VT and Chu E. A History of Cancer Chemotherapy. Cancer Res. 2008; 68:8643- 53.
32. Saijo N, Nishio K, Tamura T. Translational and clinical studies of target-based cancer therapy. Int J Clin Oncol. 2003; 8:187-92.
33. Fabian MA, Biggs WH, Treiber DK. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotech. 2005; 23:329-36.
34. Voldborg BR, Damstrup L, Spang-Thomson M et al. Epidermal Growth Factor Receptor (EGFR) and EGFR mutations, function, and possible role in clinical trials. Ann Onc. 1997; 8:1197-1206.
35. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001; 37:9-15.
36. Slamon DJ, Leyland-Jones B, Shak S et al. Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2. N Engl J Med. 2001; 344:783-92.
37. Ross JS, Fletcher AJ, Linette GP et al. The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. The Oncologist. 2003; 8:307-25.
38. Bareschino MA, Schettino C, Troiani T et al. Erlotinib in cancer treatment. Ann Onc. 2007; 18:35-41.
39. Gridelli C, Bareschino MA, Schettino C et al. Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. The Oncologist. 2007; 12:840-9.
40. Ono M and Kuwano M. Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs. Clin Cancer Res. 2006; 12:7242-51.
41. Ross JS, Fletcher JA, Bloom KJ et al. Targeted Therapy in Breast Cancer: the HER2/neu gene and protein. Mol Cell Proteomics. 2004; 3.4:379-98.
42. Hudis CA. Trastuzumab-Mechanism of Action and Use in Clinical Practice. N Eng J Med. 2007; 357:39-51.
43. Steeghs N, Nortier JWR, Gelderblom H. Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: And Update of Recent Developments. Ann Surg Onc. 2006; 14:942-53.
44. Moy B, Kirkpatrick P, Kar S, Goss P. Lapatinib. Nat Rev Drug Discov. 2007; 6:431-2.
45. Hayes DF, Miller K, Sledge G. Angiogenesis as targeted breast cancer therapy. The Breast. 2007; 16:S17-9.
46. Salter JT and Miller KD. Antiangiogenic Agents in Breast Cancer. Cancer Investigation. 2007; 25:518-26.
47. Ho QT and Kuo CJ. Vascular endothelial growth factor: Biology and therapeutic applications. Int J of Biochem and Cell Biol. 2007; 39:1349- 57.
48. Sato Y. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int J Clin Oncol. 2003; 8:200-6.
49. Augustin HG. Translating angiogenesis research into the clinic: the challenges ahead. British J Radiol 2003; 76:S3-10.
50. Huguet F, Giocanti N, Hennequin et al. Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells. Mol Cancer Ther. 2008; 7:398-406.
51. Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk and Lymph. 2008; 49:19-26.
52. Joske DJL. Chronic myeloid leukaemia: the evolution of gene-targeted therapy. MJA. 2008; 189:277-82.
53. Barni S and Mandalà M. Chemotherapy for metastatic breast cancer. Annals of Oncol. 2005; 16:23-7.
54. Orlando L, Colleoni M, Fedele P et al. Management of advanced breast cancer. Annals of Oncology. 2007; 18:74-6.
55. Welch DR, Steeg PS, Rinker-Schaeffer CWR. Molecular biology of breast cancer metastis; Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res. 2000; 2:408- 16.
56. Stevanovic A, Lee P, Wilcken N. Metastatic Breast Cancer. Aust Fam Physician. 2006; 35:309-12.
57. Sarkadi B, Homolya L, Szakács G et al. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev. 2006; 86:1179- 236.
58. Sauna ZE and Ambukdar SV. About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther. 2007; 6:13- 23.
59. Hardwick LJ, Velamakanni S, van Veen HW. The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Phamacol. 2007; 151:163-74.
60. Eom Y-W, Kim MA, Park SS. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene. 2005; 24:4765-77.
61. Okada H and Mak TW. Pathways of Apoptotic and Non-Apoptotic Death in Tumour Cells. Nat Rev Cancer. 2004; 4:592-603.
62. Ashkenazi A and Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest. 2008; 118:1979–90.
63. Behbod F and Rosen JM. Will cancer stem cells provide new therapeutic targets? Carcinogenesis. 2004; 26:703-11.
64. Bjerkvig R, Tysnes BB, Aboody KS et al. The origin of the cancer stem cell: current
controversies and new insights. Nat Rev Cancer. 2005; 5:899-904.
65. Locke M, Heywood M, Fawell S et al. Retention of Intrinsic Stem Cell Hierarchies in Carcinoma-Derived Cell Lines. Cancer Res. 2005; 65:8944-50.
66. Smalley M and Ashworth A. Stem Cells and Breast Cancer: A Field in Transit. Nat Rev Cancer. 2003; 3:832-44.
67. Al-Hajj M and Clark MF. Self-renewal and solid tumor stem cells. Oncogene. 2004; 23:7274- 82.
68. Lawson DA and Witte ON. Stem cells in prostate cancer initiation and progression. J Cln Invest. 2007; 117:2044-50.
69. Hill RP and Perris R. “Destemming” Cancer Stem Cells. J Natl Cancer Inst. 2007; 99:1435- 40.
70. Croker AK and Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med. 2008; 12:374-90.
71. Wright MH, Calcagno AM, Salcido CD et al. Brca1 breast tumors contain distinct CD44+/CD24– and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008; 10:R10.
72. Wicha MS. Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res. 2008;10(2):105.
73. Saijo N, Nishio K, Tamura T. Translational and clinical studies of target-based cancer therapy. Int J Clin Oncol. 2003; 8:187-92.
74. Hermiston TW and Kirn DH. Genetically Based Therapeutics for Cancer: Similarities and Contrasts with Traditional Drug Discovery and Development. Mol Ther. 2005; 11:496-507.
75. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001; 98:10869-74.
76. Hinestrosa MC, Dickersin K, Klein P et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer. 2007; 7:309-15.
77. Azad NS, Rasool N, Annunziata CM et al. Proteomics in Clinical Trials and Practice; Present Uses and Future Promise. Mol Cell Proteomics. 2006; 5:1819- 29.
78. Tan DSP, Lambros MBK, Natrajan R et al. Getting it right: designing microarray (and not ‘microawry’) comparative genomic hybridization studies for cancer research. Laboratory Investigation. 2007; 87:737-54.
79. Clarke R, Ressom HW, Wang A et al. The properties of highdimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer. 2008; 8:37-49.
80. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteosome system. Nat Rev Drug Discov. 2006; 5:596-613.
81. Petroski MD. The ubiquitin system, disease, and drug discovery. BMC Biochem. 2008; S1-7.
82. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res. 2006; 12:6869-75.
83. Fumoleau P, Coudert B, Isambert N et al. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and regulated analogues. Ann Oncol. 2007; 18:9-15.
84. Fojo T and Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Onc. 2007; 18: v3-8.
85. Futamura M, Kamiya S, Tsukamoto M et al. Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene. 2001; 20:6724- 30.
86. Sah NK, Munshi A, Kurland JF et al. Translation Inhibitors Sensitize Prostate Cancer Cells to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis inducing Ligand (TRAIL) by Activating c-Jun Nterminal Kinase. J Biol Chem. 2003; 278: 20593-602.
87. Radhakrishnan SK and Gartel AL. A Novel Transcriptional Inhibitor Induces Apoptosis in Tumor Cells and Exhibits Antiangiogenic Activity. Cancer Res. 2006; 66:3264-70.
88. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov. 2002; 1:111-21.
89. Reed JC and Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005; 106: 408-18.
90. Dai Y, Lawrence TS, Xu L. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res. 2009; 1:1-15.
91. Schimmer AD. Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice. Cancer Res. 2004; 64:7183-90.
92. Ziegler DS and Kung AL. Therapeutic targeting of apoptosis pathways in cancer. Current Opinion in Oncology. 2008; 20:97-103.
93. Sharkey RM, Karacay H, Cardillo TM et al. Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods. Clin Cancer Res. 2005; 11:7109s-21s.
94. Jain KK. Nanotechnology-based Drug Delivery for Cancer. Technology in Cancer Research & Treatment. 2005; 4:407-16.
95. Rawat M, Singh D, Saraf S et al. Nanocarriers: promising vehicles for bioactive drugs. Biol Pharm Bull. 2006; 29:1790-8.
96. Jain KK. Applications of Nanobiotechnology in Clinical Diagnostics. Clinical Chemistry. 2007; 53:2002–9.
97. Thomson TA, Hayes MM, Spinelli JJ et al. HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization. Mod Pathol. 2001; 14:1079-86.
98. Ellis CM, Dyson MJ, Stephenson TJ et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005; 58:710–4.
99. Barrett C, Magee H, O’Toole et al. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: falsepositive or false-negative immunohistochemistry? J Clin Pathol. 2007; 60:690-69.
100. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266: 2011-5.
101. Hoos A, Hepp HH, Kaul S et al. Telomerase Activity Correlates with Tumor Aggressiveness and Reflects Therapy Effect in Breast Cancer. Int J Cancer. 1998; 79:8-12.
102. Herbert BS, Wright WE, Shay J. Telomerase and breast cancer. Breast Cancer Research. 2001; 3:146-9.
103. Hahn WC, Stewart SA, Brooks MW et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999; 5:1164-70.
104. Zhang X, Mar V, Zhou W et al. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999; 13:2388-99.
105. Herbert BS, Pitts AE, Baker SI et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA. 1999; 96:14276-81.
106. Shay JW and Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev. 2006; 5:577-84.
107. Gellert GC, Jackson SR, Dikmen ZG et al. Telomerase as a therapeutic target in cancer. Drug Discovery Today: Disease Mechansisms. 2005; 2:159-64.
108. Hochreiter AE, Xiao H, Goldblatt EM et al. The telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth andmetastasis of breast cancer. Clin Cancer Res. 2006; 12:3184-92.
109. Jackson SR, Zhu CH, Paulson V, Watkins L, Dikmen ZG, Gryaznov SM, Wright WE, Shay JW. Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase. Cancer Res. 2007;67(3):1121-9.
110. Ghoshal A. Translational Research in Oncology: Implications for Palliative Care. Indian J Palliat Care. 2017; 23(4): 462-7.
111. Wainwright SP, Williams C, Michael M et al. From bench to bedside? Biomedical scientists' expectations of stem cell science as a future therapy for diabetes. Soc Sci Med. 2006; 63:2052–64.
112. Pincus HA. Challenges and pathways for clinical and translational research: Why is this research different from all other research? Acad Med. 2009; 84:411–2.
113. Heuckmann JM, Thomas RK. A new generation of cancer genome diagnostics for routine clinical use: Overcoming the roadblocks to personalized cancer medicine. Ann Oncol. 2015; 26:1830–7.
114. Baudino TA. Targeted cancer therapy: The next generation of cancer treatment. Curr Drug Discov Technol. 2015; 12:3– 20.
115. NIH. Targeted Cancer Therapies Fact Sheet. National Cancer Institute. 2014; 1–6.
116. Mogil JS. Animal models of pain: Progress and challenges. Nat Rev Neurosci. 2009; 10: 283–94.
117. Watson M, Lucas C, Hoy A et al. Oxford Handbook of Palliative Care. Ch. 4. Oxford: Oxford University Press; Principles of drug use in palliative care. 2009.
118. Rai AJ. Biomarkers in translational research: Focus on discovery, development and translation of protein biomarkers to clinical immunoassays. Expert Rev Mol Diagn. 2007; 7:545–53.
119. Reid VL, McDonald R, Nwosu AC et al. A systematically structured review of biomarkers of dying in cancer patients in the last months of life; An exploration of the biology of dying. PLoS One. 2017; 12:e0175123.
120. Lillie EO, Patay B, Diamant J et al. The n-of-1 clinical trial: The ultimate strategy for individualizing medicine? Per Med. 2011; 8:161–73.
121. Farrar JT. Understanding clinical trials in palliative care research. Vol. 1. Oxford: Oxford University Press; 2015.
122. Rosenberger WF, Huc F. Maximizing power and minimizing treatment failures in clinical trials. Clin Trials. 2004; 1:141–7.
123. Boers M. Add-on or step-up trials for new drug development in rheumatoid arthritis: A new standard? Arthritis Rheum. 2003; 48:1481–23.
124. Hui D, Zhukovsky DS, Bruera E. Which treatment is better? Ascertaining patient preferences with crossover randomized controlled trials. J Pain Symptom Manage. 2015; 49:625–31.
125. Bouça-Machado R, Rosário M, Alarcão J et al. Clinical trials in palliative care: A systematic review of their methodological characteristics and of the quality of their reporting. BMC Palliat Care. 2017; 16:10.
126. Currow DC, Plummer JL, Kutner JS et al. Analyzing phase III studies in hospice/palliative care. a solution that sits between intention-to-treat and per protocol analyses: The palliative-modified ITT analysis. J Pain Symptom Manage. 2012; 44:595–603.
127. Farquhar MC, Prevost AT, McCrone P et al. Study protocol: Phase III singleblinded fast-track pragmatic randomised controlled trial of a complex intervention for breathlessness in advanced disease. Trials. 2011; 12:130.
128. Kramer MS, Shapiro SH. Scientific challenges in the application of randomized trials. JAMA. 1984; 252:2739-45.
129. Aktas A, Walsh D. Methodological challenges in supportive and palliative care cancer research. Semin Oncol. 2011; 38:460-6.

Most read articles by the same author(s)